Ankylosing spondylitis Market Size and Share
Ankylosing spondylitis (AS), also called Bechterew's disease is a form of arthritis that primarily affects the spine, although other joints may also be involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort. It is a type of axial spondyloarthritis (axSpA) that refers to a particular form of spondyloarthritis in which the predominant symptom is inflammatory back pain.
DelveInsight's " Ankylosing spondylitis Market Insights, Epidemiology, and Market Forecast 2030 " report delivers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the United States, EU5 (Germany, Spain, Italy , France, and United Kingdom) and Japan.
Ankylosing spondylitis Market Key Facts
Ankylosing spondylitis is considered to be more prevalent in men as compared to women.
There were 1,389,116 prevalent cases of Ankylosing Spondylitis in 2017 in 7MM. These prevalent cases are further expected to increase for the study period 2017–2030.
Japan had the lowest prevalent population of Ankylosing Spondylitis in 2017 with 7,540 cases in 2017.
AS is found to be more prevalent in men as compared to women, with around 358,880 male and 146,585 female cases in 2017 in the United States. Further in case of severity, majority of cases belong to stable AS (mild), as compared to active AS (moderate to severe)
Ankylosing Spondylitis Market Size and Share
The Ankylosing spondylitis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Ankylosing spondylitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Ankylosing spondylitis market Size and share of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Ankylosing Spondylitis Epidemiology
The Ankylosing spondylitis epidemiology section covers insights about historical and current Ankylosing spondylitis patient pool and forecasted trends for every seven major countries (ie the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Ankylosing Spondylitis Pipeline Insights and Key Market Players
The Ankylosing spondylitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ankylosing spondylitis market or expected to get launched in the market during the study period. The analysis covers Ankylosing spondylitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Ankylosing Spondylitis market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2018-2030. Some of the key companies in the Ankylosing spondylitis market include Pfizer, Galapagos NV, UCB Biopharma, Sun Pharmaceuticals/Merck and Co., Abbvie, Kyowa Kirin, and others.
For more details visit: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-market